Inovio Pharmaceuticals Inc vs Meta Platforms Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Meta Platforms Inc trades at $582.5 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 19478× Inovio Pharmaceuticals Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | META | |
|---|---|---|
Market Cap | $78.55M | $1.53T |
Sector | Health | Media |
52-Week High | $2.87 | $790.00 |
52-Week Low | $0.66 | $525.72 |
Enterprise Value | $49.56M | $1.55T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
META stock trades at $581.30, down 2.29% over 24 hours. The technical picture is neutral, with the price near key support at $580. Fundamentally, the company reported strong revenue of $200.97B for 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a significant legal ruling in Massachusetts.
The outlook is positive, supported by a strong analyst consensus (79% Buy) and a $761.95 price target. Key opportunities include AI monetization and revenue growth, while risks involve high capital expenditure, legal challenges, and competitive pressures in the social media and AI sectors.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →